Trinity Capital Inc. Provides $15 Million in Growth Capital to Cagent Vascular Inc.

Group 1: Investment Announcement - Trinity Capital Inc. has committed $15 million in growth capital to Cagent Vascular Inc., which is a significant addition to the$45 million equity financing led by US Venture Partners in 2024 [1][4] - This investment aims to support Cagent Vascular's innovative vascular treatment technologies, particularly their flagship product, Serranator®, which enhances angioplasty procedures [2][4] Group 2: Company Overview - Cagent Vascular Inc. specializes in developing advanced endovascular solutions to improve patient outcomes in minimally invasive interventions, particularly for peripheral artery disease [2][6] - The company's Serration technology has been utilized in over 20,000 procedures, demonstrating a growing body of clinical evidence supporting its effectiveness [4][6] Group 3: Strategic Partnership - Trinity Capital expresses excitement about partnering with Cagent Vascular to expand their platform of solutions for treating peripheral artery disease [3][4] - Cagent Vascular's leadership emphasizes the importance of this additional capital in scaling their commercial infrastructure and accelerating clinical adoption of their technologies [4]